small molecule

ROWASA

MESALAMINE

Loss of exclusivityloss of exclusivity
CompanyMYLAN SPECIALTY LP

Drug detail

Brand nameROWASA
Active ingredientMESALAMINE
Strength4GM/60ML
Dosage formENEMA
RouteRECTAL
ModalitySmall molecule
FDA approvalDecember 1987
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ROWASA patent cliff — loss of exclusivity — | CliffBio